IJPHT Journal
Papers Having Good Impact
International Journal of Pharmacy and Herbal Technology-ISSN NO: 2583-8962 (Online)

Review on:- Quality Control and Quality Assurance

S.D Sonawane,Sanjay K Bais,Rutuja U Dhandore
Fabtech college of Pharmacy,Sangola

ABSTRACT :

In every business quality is the first priority for the product as it directly affects the revenue from sales. However, there is another important reason why the pharmaceutical industry needs quality products.Errors in the manufacturing process can cause harm or even death to patients who consume the product, and this is one of the main reasons for the strict industry. Therefore, drug production needs to be strictly regulated.The purpose of the quality control department in the pharmaceutical industry is to ensure continuous review of the quality characteristics of pharmaceutical products. All raw materials, materials and finished products used in production are tested to ensure the desired quality. Environmental inspection is carried out to ensure that products are produced, packaged and stored in accordance with specifications.The equipment operates and is calibrated as planned.Screening methods are continually improved and validated to ensure they continue to produce reliable and consistent results.In the current situation, the background becomes very important.Each production is certified by selected personnel and made available before purchase.Since pharmaceutical products come directly from patients, necessary precautions have been taken to ensure that the pharmaceutical industry benefits from quality control, and therefore the identity, purity ,The safety and suitability of the final product is crucial

The entire pharmaceutical industry must comply with many international guidelines that set rules and standards.The legal system that determines activities, processes and procedures to achieve quality policies and objectives is called quality management .Quality management helps to improve and control the organization's work to meet legal and customer requirements and to continuously improve its results and performance.[1]

Keywords: (Quality control ,Quality Assurance,cGMP, IND NDA ,ANDA, sNDA,)

INTRODUCTION:

After receiving FDA approval is just the first step in another extremely difficult journey. There are obstacles to overcome when moving a drug formulation from the lab to the production line. The history of cGMP makes this clear: there are a lot of things that can go wrong, and it's crucial to have enough control over the variables that can Impact the drug product's ultimate quality.Pharmaceutical companies relied heavily on Quality Control (QC) for several years to ensure that the quality of their products was adequately tested. But as processing operations became more intricate over time, it became clear that testing frequently fails to identify issues because it is conducted on randomly chosen samples. It is impossible to "test" quality into products that lack inherent quality. The

idea of quality assurance (QA), which aims to incorporate quality into the products from the outset of the medication manufacturing process, was developed as a result of this realisation. Processes can be controlled by meticulous planning, training, and monitoring QA, which includes selecting the best supplier for the beginning and packing materials and how the right vendor for the beginning and packing materials can be chosen, and processes can be carefully planned, trained, and monitored with the help of quality assurance (QA).[2]

Definitions:

Quality control: The World Health Organisation defines quality assurance as a component of good manufacturing practise (GMP) that deals with sample Features and tests as well as organisation, recording, and emit procedures. These procedures make sure passed all necessary test ,goods or materials for purchasing goods or materials insofar as they are of interest.

Quality assurance is a systematic approach to guaranteeing product reliability as it is being developed.[3]

Table no.1 The distinction between quality assurance and control

Aspects	Control of Quality	Quality Assurance
1)Goal	Identifying defects	Preventing defects
2) Focus	Testing if quality exist in product after its manufacturing	Building quality into product from design stage itself
3)work flow	Find source of problem	Establish quality management system, continuous monitoring process
4)Type of tool	Corrective	Managerial

Scopes of quality Control:

• To find defects in the finished product • To find defects in a product both during development and prior to Release

Figure.1: Scope of Quality Control

- Identifying the causes of quality issues so that you can consistently satisfy customers' needs.

- Analytical methods for maintain process and product quality.

Figure.2: Quality Assurance

Scope of quality assurance

1)To stop errors while keeping the process in mind.

2)To enhance the testing and development procedures to prevent errors.

3)Create a strong quality management system and evaluate its effectiveness over time.

4)Prevention of issues with quality by means of organised and methodical actions

- **Guidelines for manufacturing excellence**

  Production is called GMP. "This is part of quality control and wanting products to be produced correctly in accordance with the degree of quality, suitability for the purpose for which they are used and the rules of procedure for business approval" means good management. . Reducing hazards associated with the manufacturing of pharmaceutical products is the primary goal of GMP. We can divide these hazards into two main groups:

  1)contamination (especially when there are questionable products) and confusion (confusion) caused by reasons such as incorrect labels on packaging.

  2)Production and quality assurance are handled as follows: Quality Assurance. Most regulators (FDA).

- **cGMP** provides systems to ensure the qualification,Monitor and control production facilities and processes. Comply with cGMP regulations to ensure identity, potency,

quality and purity of pharmaceutical products by requiring pharmacists to control the manufacturing process. Use approved operating procedures or SOPs for reporting, data collection, emissions measurement, uncertainty estimation and verification, and calculation when collecting data technique .

- What are cGMP

Sometimes, "cGMP" is used instead of GMP.

▫Current Good Manufacturing Practices (cGMP) are regulations set by the US Food and Drug Administration.[4]

APPROPRIATE MANUFACTURING STUDIES:

The federal Food, Drug, and Cosmetic Administration has authorized the FDA to issue Good Manufacturing Practices (GMPs).These rules mandate that producers, distributors, and manufacturers of pharmaceuticals, medical equipment, certain foods, and blood maintain quality standards. To guarantee the products' efficacy, purity, and safety, they must guarantee their quality. GMP regulations govern good manufacturing practices that help organizations reduce or eliminate the potential for contamination, errors, and confusion. Therefore, consumers will not purchase products that do not work or have problems.Companies that violate GMP regulations are subject to severe penalties such as recalls, seizures, fines and imprisonment.

- **Component of GMP**

1) Quality management system
2) Personnel
3) Facilities and equipment
4) Sanitation and hygiene
5) Documentation and record keeping
6) Raw material and components
7) Manufacturing process
8) Packaging and labelling
9) Quality control
10) Product complaints and recall
11) Validation and qualification
12) Change control
13) Audits and inspections
14) Training and continuous improvement[5]

GLP : GOOD LABORATORY PRACTICES

To assess whether chemicals and chemical products are safe, one must first have faith inscientific methods and findings. Whether a study is being conducted in an academic, industrial, or contract laboratory, the fundamental scientific methods must be applied rigorously and thoroughly for safety decisions.These core scientific ideas and practises serve as the foundation for Good Laboratory Practise (GLP) regulations, which are essential for

ensuring scientific credibility in investigations carried out to determine chemical safety. These reasons illustrate why governments around the world are mandating GLP compliance and why GLP studies should be given more weight than published non-GLP studies, according to the paper Myers et al. (2009) argue in their review that research should not be excluded from decision-making simply because it fails to comply with GLP While we agree that GLP should not be important, we agree with the authors' lack of understanding of GLP's purpose and role and their claims that GLP is ineffective.The safety of a product should be evaluated by reviewing all relevant studies using the weight of the evidence. Scientific principles should guide the evaluation and weighting of all studies, even if they comply with GMP

Evaluation criteria include:

- confirmation of data and measurement techniques
- Manage experimental changes that may affect evaluation
- cross-study correlation
- Statistics and biological abilities
- Generalizability of effects to animal-related diseases and appropriate exposure in the actual testing process
- Biological plausibility of study results

The US National Toxicology Program (NTP), US Food and Drug Administration (FDA), and Environmental Protection Agency (EPA) require these studied to comply with GLP (FDA 2005; NTP operation and development (OECD) (OECD 1998) are substantial for all OECD nations

How to Run a Non-Clinical Laboratory Investigation:

This is an important part of the GLP and any breach of this will result in a report from the regulator. Prerequisites are as follows:

1)The protocol must be followed when conducting the non-clinical laboratory study. There is no excuse for the protocol violation.

2)Every clinical observation made on test animals must adhere to the study protocol.

3)The test, study type and collection date should be clearly written on the box.In order to avoid recording errors and keep a record, this information must be stored in the sample container or placed inside the sample

4)A pathologist conducting a histopathology study will have access to the clinical observations made during the investigation as well as the corresponding records. A correlation between the two will be determined.

5)The generated data must be promptly and clearly recorded in pen (unless it is data that has been captured electronically). No entries may be altered, and if they are, they must be justified and signed by authorised staff.

6)Made, it shall The person entering the data must be identified for automated data collection systems.

7)Any modifications to an entry must not overshadow the original, and the responsible person or authority's signature must be included along with the explanation for the modification.[5]

- **Drug development and discovery :**

In early period of human civilization,At that time, medicine was discovered by chance or natural observation. They often, but not always, involve the extraction of ingredients from plants or animals that are used not only to treat physical ailments but also for spiritual healing.The early 1900s saw the beginning of modern drug discovery. Currently, preliminary discovery of new drug development often begins with simple studies, usually done in academia, to identify macromolecules (large molecular weight molecules such as genes or proteins), dysfunctional signaling pathways, or molecular mechanisms that appear to be related illness.



Figure .3 Drug design and discovery

To explain the main stages with a very simple example, the different methods depend on the type of therapy that needs to be developed and the molecular mechanisms at play in the disease The entire process will take 12 to 15 years to complete and is expected to cost $2.8 billion.Now, we will examine this process in more detail, taking this small discovery as an example. In general, the first methods focus on specific organisms and find can be affected by small items,usually proteins. This medications should arrest or halt the disease or at least slow the onset of symptoms. Various methods such as proteomic analysis, genomic studies, and cell analysis can be used to identify these targets.Thousands, millions or Testing millions of small molecules in different types of assays, selecting a few risky molecules and evaluating them in animal models (another way to develop drugs).Creature models can be misdirecting; for

illustration, a sedate that's harmful in creature models might not be harmful to people, or bad habit versa (Pognan et al., 2023). Thinks about on assimilation, dissemination, and end (ADME) are carried out concurrently. A number of compounds will ideally be secure and viable sufficient to move on to persistent trials after a long time of inquire about. In summary, the different phases have different names, but they are usually referred to as follow-up: preliminary research and basic research (usually 5-7 long periods), where the aim and minor changes are considered ex vivo (e.g. in tissue). Or body), in vitro (i.e. in an in vitro laboratory) and in silico (i.e. using a computer).By and large talking, exceptionally few compounds proceed on to the following stage after all of these strategies.

Recently, at least two biological models (one from rodents (e.g. mice); if animals do not have mice (such as mutts, small dogs) – pigs) – different courses are often used.An application known as an Investigational Unused Sedate (IND) is recorded to administrative bodies (such as the Nourishment and Medicate Organization within the US) some time recently clinical trials start.Biosufficiency and hazard information (Good Manufacturing Practices (GLP) biotoxicological information supporting dosage, time of use, organization), production information and medical guidelines are generally included in this text, at least so far (See below).Detailed information on the manufacturing process, proposed clinical parameters for the clinical trial (e.g. patients, number of patients, study duration) and summary about the investigators.• In a few cases, such as cancer, trials called phase 0 may start, in which modern drugs are utilized in a little number of individuals and now and then in patients.

The aim of this discussion is to swiftly resolve the functioning of the medication.

- Phase 1 involves testing the drug's safety and longevity in a limited number of healthy individuals.

  (e.g. 20-80 people) (usually an initial one-off study, followed by a series of short courses).
- Phase II studies can be conducted in multiple hospitals across multiple nations, with an average of 100–500 patients participating.
- This study seeks to ascertain whether the patient requires medical attention. Phase 2 trials include more comprehensive safety studies Phase IIa is the first phase of Phase II and is designed to optimize the dose needed for the patient to achieve the desired treatment or endpoint.
- . Phase IIa is the first phase of Phase II and is designed to optimize the dose needed for the patient to achieve the desired treatment or endpoint. Phase IIa studies can begin after appropriate dose levels are established.

  Finding the candidate medication overall effectiveness in a small subject population is the aim of phase IIa. In phase II, many drug candidates are unsuccessful because of ineffectiveness or safety concerns

Phase III focuses on investigating the effects of the candidate drug in a larger sample of patients.

These trials, which are often randomised and encompass 1,000–5,000 patients at several clinical settings, are intended to assess how well prospective medications work in comparison to the gold standard of treatment or a placebo,obtain information about potential drug interactions, and re-evaluate all drug interactions. Dosage (the ideal dose is important for effective use of the drug).

A double-blind study is one in which neither the patient nor the doctor is aware of the treatment the patient is receiving.

Depending on the ailment under investigation and the intended outcome of the treatment, this step may take different amounts of time and money.

Phase III clinical trials are the most costly stage of drug research and development since they are challenging to plan and necessitate a high patient tally.

During development, design and stability research is also carried out (both in batch and world permit circumstances) in order to identify the optimal formulation and describe the contaminants that are present.

A positive “risk-benefit ratio” is a must. Priority is given to medications that significantly improve a condition’s course of treatment. Regulatory bodies’ approval, however, does not mean that clinical trials are over.

- Long-term follow-up studies, often called Phase 4 or post-marketing evaluations (also called “global evidence” trials), are frequently mandated by regulatory bodies.
- The goal of these research is typically to identify less severe or long-term adverse effects in bigger patient populations.
- Phase 4 studies may lead to changes based on safety assessments, warnings about the use of new drugs in existing treatments, or in extreme cases, withdrawal of drugs permitted for trade.[6,7,8]

OVERVIEW OF DRUG DEVELOPMENT:

- Determining and overseeing the drug research and approval procedure has taken years for the Food and Drug Administration (FDA) in the United States.
  Safety is always his top focus, then effectiveness.The drug sponsor or sponsor may submit an application for an Investigational New Drug (IND) if the drug shows promise in exploratory studies.
  Recommendations include all medication and medical records, investigator qualifications, and requests for exemptions from federal state carry restrictions. Not recommended drugs
  Once approved, Once the medication has been investigated (Phase I–III trials are detailed below), the drug sponsor may file a New Drug Application, also called an NDA, with the FDA if it is determined being effective and secure in the intended population.

A New Drug Application (NDA) may be submitted to the FDA by the drug sponsor when the drug's safety and efficacy in the intended population have been established.

The FDA decides whether to approve and market medicinal medications after careful review, which often includes recommendations from external committees.Final approval will be based on a phase 4 trial evaluating The medication's efficacy and safety in the intended audience

To make it easier to evaluate and validate foreign medicinal product (ICH) data, initiatives were made to harmonise the approval procedures in the US, Europe, and Japan by the International Meeting on Harmonisation of Technical specifications to The registration process about Drugs for Human Use.[9]

- **Clinical research process:**

Clinical research is a subfield of medical science that evaluates the efficacy and security of medications,

Products, diagnostic equipment, and medical preparations for human consumption.

• Research is a tedious and time-consuming process that takes years to complete. Drug research, in particular, is time-consuming and labor-intensive; It takes approximately 13.5 years the average cost bring a new medicine to market is $1.7 billion.

A clinical trial is any type of research where groups or individuals are prospectively assigned to one or more interventions related to health in order to assess the impact on health outcomes.

• The purpose of conducting clinical trials is to gather data regarding the efficacy and safety of novel medications and medical technologies. The pioneer of experimental medicine is James Lind.

- **The Importance of Clinical Research**

• Clinical research is developing new treatments for existing diseases as well as new methods to detect, diagnose and reduce risk

• Clinical trials can teach researchers information about human behavior that cannot be learned in the lab or on animals, such as what works and what doesn't.

• Clinical trials also help health care providers determine whether the side effects of a new treatment can be tolerated when considering its possible benefits.

- The IND application needs to contain the following items:

1)Data from animal studies and toxicity tests
2)Producing data
3)Clinical guidelines (plans of study) for up
coming investigations
4)Information from any earlier studies involving humans
5)Details about the researcher
6)Any extra information

Investigation new drug application Examining novel pharmaceutical applications

The drug producer or sponsor may start a clinical trial following the completion of preclinical investigations by completing the Investigational New Development (IND) registration to regulatory bodies such as the U.S. Food and Drug Administration (FDA), India CDSCO, etc.

After the IND was submitted, all the data was reviewed by the appropriate regulatory authority, and if they were satisfied, they gave the sponsor permission to begin the clinical trial. For 30 days, it will come after.IND submission in order to obtain clinical study approval.

Stage of Drug Development Known as Clinical:

Pre-clinical research can provide a basic understanding of an animal model's pharmaceutical safety, but it is not appropriate to utilise animal models in place of humans for clinical trials. Research projects or experiments labelled as "clinical research"
Test the efficacy and safety of drugs on human subjects Examining novel pharmaceutical applications

Clinical studies are divided into four phases:

- **Stage1**
  Participants in the study: 20–100 fit individual
  Study Period: Several months to a year
  Goal: Dose range and safety
- The Second Phase
  Participants in the study: 100–300 volunteers who have the illness
- **Stage 2**
  About 300 to 100 volunteers with the illness were included in the study.
  Study Period: Up to Two Years
  Goals: Safety and Effectiveness
- **Stage 3**
  300–3,000 volunteers with the target disease are part of the study.
  Study Period: One to Four Years
  Goals: Verify Long-Term Safety and Efficacy, Track Adverse Reactions
- **Stage 4**
  Postmarketing surveillance [13,14]

Figure .4 Clinical trial phases



NDA Application

Drug regulators in the US have been pursuing New Drug Applications (NDAs) for years. Since 1938, a new drug application Before a medication is sold in the US, the NDA must be authorised.

Through an NDA, the pharmaceutical company has requested approval from the US Food and Drug Administration to market and sell the novel medication domestically

To create a new drug application (NDA), integrate findings from animal research and investigational new drug (IND) application



Figure 5 IND Application

A new drug application's (NDA) goal is to give FDA reviewers enough data to enable them to decide if the medication is effective as well as secure. Use or purpose, as well as if the risk is justified.

Shortened shape for modern medications Application: (ANDA)

ANDA brief for shortened unused medicate application, may be a formal request to the FDA (Nourishment and Medicate Organization) looking for authorization to make and advertise a branded medicate inside the Joined together States. Truncated unused medicate applications are named "abbreviated" since they don't require as much data as a unused sedate application and don't require the candidate to do clinical research.

The abbreviated new drug application (ANDA) is the document that the US Food and Drug Administration (FDA) uses to approve the manufacturing and distribution of generic medications within the nation.

The new registrations are called “abbreviated” because they require less information than new drug applications and do not require applicants to conduct clinical trials. The ANDA lists the name of the newly developed drug, its trade name, if any, the name of the drug, dosage form, dose, method of application and recommended use. The suggested generic drug product’s name is required by the ANDA in order to determine its equivalent.ANDA also indicates whether the drug is available over-the-counter or by prescription only and whether it is used to treat a rare disease.ANDA also indicates whether the drug is available over-the-counter or by prescription only and whether it is used to treat a rare disease.It can be necessary for applicants to provide more data on chemical compounds, manufacturing and control processes, and other topics.

The generic medication is scheduled to be introduced to the Orange Book, a list of medications that what the Food and Drug Administration has determined are secure and accessible to the general public, if the ANDA is accepted.The FDA can assess a generic drug’s efficacy and safety in comparison to a brand-name medication by using the data in ANDAs.The FDA is unlikely to authorise a drug if it cannot be as secure and successful as the name-brand medication.

• ANDA applications by generic pharmaceutical companies typically occur when patent protection for a branded drug is about to expire. Therefore, if you announce your ANDA submission, it may be rejected. The rise in the stock prices of well-known pharmaceutical companies and those of generic pharmaceutical companies opens up new revenue streams for the latter. Investors should perform due diligence by reviewing a pharmaceutical company’s 10-K filing when filing an ANDA.It is important to note that submission of an ANDA does not guarantee FDA approval.The US Food and Drug Administration (USFDA) is the primary regulatory body in charge of overseeing new drug applications and approvals. The Federal Food, Drug, and Cosmetic Act (FD&C Act) serves as the foundation for this examination.
(FD&C Act) Title IV application process according to FDA guidelines.

The drug cannot be sold until it is approved by regulatory authorities. ANDAs are for companies that want to copy brand-name drugs before their patents expire in order to make a profit.

.



Figure .6 ANDA Application

It includes a “certificate” submitted to the FDA by the drug sponsor, stating that the patents are covered by an FDA-approved drug (Orange Book), which includes an evaluation of clinical equivalence. It must be included in the generic drug application.

.. Generic drugs must meet FDA standards for drugs on the Reference List of Drugs (RLD). This study completes the FDA ANDA application process and takes action upon paragraph IV submissions, providing applicants with an overview of the review process and details on completing the eCTD format for ANDAs.[11,12,13,14,15,16]

• Supplementary new drug application:

A supplemental NDA (SNDA) filed to the FDA is based on an approved NDA for the medication or product that is currently covered.New or expanded clinical guidelines, new prescriptions, or changes are just a few reasons why additional medication may be sent.The sponsor may wish to add standards or tests, or make modifications to facilities, methods, or management in order to guarantee that the medicine has its unique identity, strength, effectiveness, and purity.Sponsors may wish to add new regulatory measures, relax restrictions in existing regulations, or remove certain guidelines regarding drugs and/or drug products.. Additionally, the sponsor may wish to develop new procedures for recycling pharmaceutical items that don’t follow specifications or extending the shelf life of drug products upon request, based on data collected according to existing new or updated safety measures.

It hasn’t been approved yet.It is crucial to remember that the SNDA mandates that the sponsor notify the other party of any modifications to any of the conditions included in the approval application, in addition to those that are already included.[17]

ADVISORY COMMITTEES:

FDA establishes advisory groups that include physicians, pharmacists, statisticians, and consumer services professionals (who are not FDA employees) within drug specialties and subspecialties.The committee’s responsibilities include reviewing information contained in new drug applications and making recommendations to FDA regarding the presence of research-based proof of efficacy and safety, sufficient study, and meticulous assessment.The Committee could also be invited to examine particular INDs, protocols, or significant issues pertaining to the chemical and pharmaceutical industries.It should be noted that the FDA often drafts a list of topics for the advisory group to review prior to the meeting.

The following is an example of the list of questions:

Are there two or more sufficient, carefully conducted trials? Was the patient group sufficiently explained? Is there enough information about the dose-response relationship? Furthermore Do you advise that the target patient group use the drug as directed by the sponsor? The FDA inspection process is summarized as follows

1) Preclinical (animal) testing.
2) Human evaluation procedures recommended by the new drug sponsor as described in the Investigational New Drug (IND) Application
3) First level training (usually 20-80 people).
4) This is a two-phase study, usually with around 300 participants.
5) Phase 3 studies usually have between 300 and 3,000 participants.
6) The time frame before the filing of a new medication application (NDA). FDA and medication sponsors hold regular meetings
7) The formal process to request FDA review of a drug product for marketing approval is to submit a New Drug Application.
8) FDA must determine whether the NDA should be submitted for review within 60 days of receipt.
9) If the FDA signs a non-disclosure agreement, the sponsor's drug safety and efficacy studies will be evaluated by the FDA review team.
10) The FDA has confirmed the information on the label and usage directions for this drug.
11))During the approval process, prospective drug makers are examined by the FDA.
12)) FDA reviewers consider the drug "approved" or "not approved. [18,19]

Supplementary NEW DRUG APPLICATION (SNDA):

This includes

1)changes to pre-validated product formulations, patient populations, and manufacturing processes.

2)The new supplement is an application that allows companies to make changes to products that have received New Drug Application (NDA) approval.

CDER must approve any significant changes to the NDA (for example, changes to ingredients or packaging) to confirm that the good still satisfies the initial specifications.

3)Supplement Number: An active FDA New Drug Application (NDA) number is associated with a supplement number. Once a drug is approved, companies may change the drug or its labelling

If a company wants to market the drug in a different dosage or dosage, change its label, or change its manufacturing process, it must submit a new supplemental drug application (sNDA). Each sNDA is usually (but not always) assigned a sequential number starting with 001.3.

4)Brand Additions Once a drug is approved, companies may change the drug or brand name.

If a company wants to market the drug in a different dosage or dosage, change its label, or change its manufacturing process, it must submit a new supplemental drug application (sNDA).

Substitution types approved by the FDA are called generics. This includes changes in the patient base, design and manufacturing.

5) Need for Change You may have a desire to change or improve a product or increase security. To meet market demand, we need to expand and add production sites.

Changes after approval include:

- Parts and construction
- production location
- production process
- specifications
- container closure system
- Labelling
- Other changes
- Related changes.

6) To support a specific change, applicants must consider all relevant CDER guidance documents and provide all required data.

7) Success modifications may potentially affect the effectiveness, safety, or quality of the product. Any changes to precertified products require FDA and CDER approval.

8) US FDA Guide to Variants There are three groups of variants based on how they may affect the drug product.

9) Distribution may be halted if the FDA does not approve it. The FDA says supplements must receive prior approval. Distribution was delayed while waiting for corrections due to lack of information. Small adjustments: Very unlikely to have a negative impact. The applicant's next annual report10 must include an explanation of any minor changes.

10) Advice on modification to appropriate product
The variation guide is divided into four appendices to help with the classification of different kinds of changes.
Appendix I is a list of minor changes that includes notification (N).
Appendix II: definition and instances of significant alternation

Annex IV: Prequalification of FPP changes and security of changes 11 12.

Annex III: Changes to be reintroduced or extended[20]

ADVISORY COMMITTEES:

This may affect the quality of your medicine. Key Change: It poses a significant risk to the drug's identity, potency, quality, purity or potency because these characteristics may affect the

drug's effectiveness or safety. These are called "pre-approvals."Fix lighting,Lighting There is a possibility of negative results.

Class 1 medications have to be filed with the FDA at least 30 days prior to distribution and must include the following information: "Additional changes will take effect within 30 days." Supplements may be classified as "Supplement – In Development" upon FDA approval.

POST MARKETING SURVEILLANCE:

Premarket trials are being conducted to determine the drug's toxicity profile; however, these tests have generally been found to be ineffective in detecting side effects of medications(ADRs).This might be because of the research participants' limitations, since some adverse drug responses (ADRs) only show up once every 10,000 exposures or fewer.The World Health Organization (WHO) defines adverse drug reactions as: preventing, diagnosing, or treating disease or altering the health of the body."“These fall into several categories including time-related, non-dose-related, dose-related and unexpected treatment failure.Follow-up is portant to monitor long-term medication use or adverse effects from taking medications for a long time.The assortment of defects associated with previous research makes it necessary to continue the study even after the drug is approved.To obtain a comprehensive comprehension of the benefits or disadvantages that the drug may have during long-term use, PMS is an important tool that helps influence drug use according to the severity of adverse events.

Post marketing surveillance:

The Committee on Medicines (CHM) and the MHRA jointly administer the Yellow Card Scheme, which is also known as MHRA PMS in the UK.One of the first PV initiatives targeted at reducing ADRs is said to have been the Yellow Card programme. PV includes the following goals:Keeping an eye on how medications are used in routine clinical settings in order to spot previously Unrecognised adverse drug reactions (ADRs) as well as shifts in adverse effect patterns Doing risk-benefit analyses for medications and making appropriate recommendations, when and if needed.Giving patients and medical professionals regular information on the safe and effective use of medications**.**

Table2: After post-marketing surveillance. Side effects to medications

Medicines	ADR with medicine
Amisulpride	Torsades de points
Cyamemazine	Torsades de points
Olanzapine	Torsades de points
Benfluorex	Valvular heart disease
Pergolide	Increased incidence of cardiac valvupathy
Hydromorphone Hydrochloride extended release	Dose dumping with alcohol

Cisapride	Palpitation,tachyarrhymia,torsades de points
Rosiglitazone	Fluid retention and Congestive heart' failure

Apart from the Yellow Card programme, the MHRA also updated the Black Triangle scheme in 2009 to provide education to the public and healthcare professionals about the quality of medicines and vaccines. Any suspected side effects from these medicines and immunizations should be reported immediately to CHM and the MHRA. The symbol is located next to the drug name and is an inverted black triangle.[21,22,23,24,25,26,27,28]

CONCLUSION:

This essay offers an outline and context of the present US regulatory approval process for the development of medicines For drug sponsors and other interested parties who want to understand Regarding the medication development procedure, the FDA has released a unique memo named ""Transforming Humane Medicine into Test Tube to Patient: Promoting Healthful Nutrition"

This article provides background information covering a range of subjects, such as reporting on dangerous medications already available on the market and studies conducted on animals and in labs.

An additional source of knowledge regarding the medication development procedure is a dynamic table of clinical trials (humans) and preclinical studies (animals) conducted by drug sponsors.

REFERENCES:

1. Pharmaceutical quality assurance book of Nirali Prakash an by assistant professor Anusuya R.kashi,Bindu sukumaran,Veena P.Page no1.1,1.3,1.5,1.7
2. Pharmaceutical quality Assurance book of pv publication by Dr.swarnali ,Das paul,Mrs.Gunjan jeswant page no 3
3. Pharmaceutical quality assurance book of Nirali prakashan by Dr Sohan chitlange ,Dr Rupali kale,Dr sanjeevani deshkar,Bhupesh patil page no 9.1,9.2,9.11
4. Nirali prakashan book of steps in quality assurance in pharmaceuticals by Dr Vijay R.salunkhe,Dr Sanjay.B.Bar page no2.7
5. FDA. Good Laboratory Practices for Conducting Nonclinical Laboratory Studies. 2005. [[accessed 6 October 2009]]. 21CFR58. Available: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58&showFR=1
6. Hefti, F. F. (2008). Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 9, S7. Doi:10.1186/1471-2202-9-S3-

7. Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., et al. (2023). The evolving role of investigative toxicology in the pharmaceutical industry. Nat. Rev. Drug. Discov. 1, 317–335. Doi:10.1038/s41573-022-00633-x

8. Kandi, V., and Vadakedath, S. (2023). Clinical trials and clinical research: A comprehensive review. Cureus 15, e35077. Doi:10.7759/cureus.35077

9. Good clinical practice guidelines for essential documents for the conduct of a clinical trial; International Conference on Harmonisation; Geneva, Switzerland: ICH Secretariat c/o IFPMA. 1994

10. https://www.investopedia.com/terms/a/abbreviated-new-drug-application-anda.asp

11. Basak AK, Raw AS, Al Hakim AH, Furness S, Samaan NI, Gill DS, Patel HB, Powers RF, Yu L: Pharmaceutical impurities: regulatory perspective for abbreviated new drug applications. Advanced drug Delivery Reviews 2007, 59(1): 64-72.

12. Hu M, Babiskin A, Wittayanukorn S, Schick A, Rosenberg M, Gong X, Kim MJ, Zhang L, Lionberger R, Zhao L: Predictive analysis of first abbreviated new drug application submission for new chemical entities based on machine learning methodology. Clinical Pharmacology and Therapeutics. 2019, 106(1): 174-181.

13. Wittayanukorn S, Rosenberg M, Schick A, Hu M, Wang Z, Babiskin A, Lionberger R, Zhao L: Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Therapeutic Innovation and Regulatory Science. 2020, 54: 1372-1381.

14. Liu Q, Davit BM, Cherstniakova SA, Dandamudi S, Walters JF, Lee CH, Raines KW, Ren K, Williamson LN, Conner DP: Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA. The AAPS Journal. 2012, 14(1): 19-22.

15. Pak T: Abbreviated New Drug Application. Threshold 2017, 614: 615

16. Biopharmaceutics Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability," Pharmaceutical Research. 1995; 12:413-20.

17. Rajkumar G: Inside Story for Review of an Abbreviated New drug Application. International Journal of Drug Regulatory Affairs 2014, 2(1): 29-31.

18. Tessman DK, Gipson B, Levins M. Cooperative fasttrack development: the fludara story. App Clin Trials. 1994; 3:55-62.

19. Food and drug administration publications; Publication No. (FDA) 02-3242.

20. http://www.fda.gov, accessed on 21/12/2007.

21. https://www.allfordrugs.com/snda/

22. Vlahović-Palčevski V, Mentzer D. Postmarketing surveillance. In: Seyberth H, Rane A, Schwab M (eds) Pediatric clinical pharmacology. Berlin: Springer-Verlag, 2011, pp.339–351

23. Hartzema AG, Porta MS, Tilson HH, et al. Adverse drug events: identification and attribution. Drug Intell Clin Pharm 1987; 21: 915–920.

24. Spelsberg A, Prugger C, Doshi P, et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017; 356: j337.

25. Poluzzi E, Raschi E, Koci A, et al. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013; 36: 467–479

26. Mullard A. Mediator scandal rocks French medical community. Lancet 2011; 377: 890–892

27. Sundaran S, Sankar S, Dhamodaran P, et al. Drug recall: an overview. WJPR 2013; 2: 297–307.

28. Quigley EM. Cisapride: what can we learn from the rise and fall of a prokinetic J Dig Dis 2011; 12: 147–156.

29. Nissen SE,The rise and fall of rosiglitazone. Eur Heart J 2010; 31: 773–776.

30. Savita Dattaray Sonawane Bais SK Saurabh Bharat Navale Introduction of Quality Control and Quality Assurance International Journal of Advanced Research in Science Communication and Technology Volume 3 Issue 1 January 2023 ISSN (online)2581-9429 P No380

31. SM Kazi SK Bais Shubham Dilip Narayankar Quality Control and Quality Assurance in Pharmaceutical International Journal of Advanced Research in Science Communication and Technologym,February 2023 3 (1) 447

32. SD Sonawane S K Bais Suyash Kamble Quality Control and Quality Assurance in Pharmaceuticals International Journal of Advanced Research in Science Communication and Technology , January 2023,3(1) 543